Avinger announces 510(k) filing for new lightbox 3 imaging console

Smaller footprint, improved user experience and lower cost to drive adoption redwood city, ca / accesswire / august 9, 2021 / avinger, inc. (nasdaq:avgr), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of peripheral artery disease (pad), today announced the submission of a 510(k) application to the u.s. food & drug administration (fda) for its new lightbox 3 imaging console. "avinger's lightbox 3 represents an important leap forward in imaging, portability and capability," commented jeff soinski, avinger's president and ceo.
AVGR Ratings Summary
AVGR Quant Ranking